Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 6OTHER 3INDUSTRY 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Radiotherapy 13Cisplatin 8Cytarabine 7carfilzomib 5Specimen Handling 5Paclitaxel 5Dexamethasone 5Methotrexate 4Lapatinib 4Gemcitabine 4Fluorouracil 4Docetaxel 4Brachytherapy 4Biopsy 4venetoclax 3pomalidomide 3Temozolomide 3Radiotherapy, Conformal 3Leucovorin 3Irinotecan 3Etoposide 3Cyclophosphamide 3Carboplatin 3neratinib 2merphos 2Vincristine 2Radiation 2Polymerase Chain Reaction 2Oxaliplatin 2Immunohistochemistry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × NETWORK × veliparib × Clear all
NCT01026493 2017-07-02

Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

Radiation Therapy Oncology Group

Phase 1/2 Completed
257 enrolled 16 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡